Recombinant Human NPPA protein

中文名： 钠尿肽前体A(NPPA)重组蛋白
别名： NPPA；MURC；Caveolae-associated protein 4

货号: PA2000-1047

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	NPPA
Uniprot No	P01160
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	78-115aa
氨基酸序列	PEVPPWTGEVSPAQRDGGALGRGPWDSSDRSALLKSKL
预测分子量	5.9 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇与NPPA(心房钠尿肽，ANP)重组蛋白相关的假设性参考文献示例(注：文献标题及作者为虚构，仅供格式参考)：

---

1. **标题**: Recombinant Human NPPA Protein Attenuates Hypertension in Rodent Models

**作者**: Zhang L, et al.

**摘要**: 研究利用大肠杆菌表达系统制备重组人NPPA蛋白，并在高血压大鼠模型中验证其降压效果。结果显示，注射重组NPPA可显著降低血压并减少心脏纤维化，提示其作为治疗心血管疾病的潜在价值。

2. **标题**: Structural Analysis of NPPA Mutants via Recombinant Expression and Crystallography

**作者**: Patel R, Kim S.

**摘要**: 通过杆状病毒-昆虫细胞系统表达并纯化NPPA突变体，结合X射线晶体学解析其三维结构。研究发现特定突变位点影响NPPA与受体NPR-A的结合亲和力，为理解其功能机制提供结构基础。

3. **标题**: Optimization of NPPA Recombinant Production in Pichia pastoris for Clinical Applications

**作者**: Müller J, et al.

**摘要**: 报道利用毕赤酵母高效分泌表达重组NPPA蛋白的工艺优化，通过发酵参数调控使产量提高5倍，并证实其生物活性与天然ANP相当，为规模化生产奠定基础。

---

注：以上为模拟文献，实际文献需通过PubMed、Google Scholar等平台检索关键词如"NPPA recombinant protein"或"recombinant ANP expression"获取。

背景信息

**Background of NPPA Recombinant Protein**

The NPPA (Natriuretic Peptide A) gene encodes atrial natriuretic peptide (ANP), a cardiac hormone primarily synthesized and secreted by the atrial myocardium in response to mechanical stretch caused by increased blood volume. ANP plays a critical role in regulating blood pressure, fluid homeostasis, and cardiovascular function by promoting vasodilation, natriuresis, and diuresis. It counteracts the renin-angiotensin-aldosterone system (RAAS), thereby reducing cardiac workload and protecting against hypertension and heart failure.

Recombinant NPPA protein is produced using genetic engineering techniques, where the NPPA gene is inserted into expression vectors (e.g., bacterial, mammalian, or yeast systems) to enable large-scale production of the bioactive peptide. This recombinant form retains the biological activity of endogenous ANP, including binding to natriuretic peptide receptor-A (NPR-A) to trigger cyclic guanosine monophosphate (cGMP)-mediated signaling pathways. Its consistent purity and scalability make it valuable for research and therapeutic applications.

In research, recombinant NPPA is utilized to study cardiovascular pathophysiology, including mechanisms underlying hypertension, heart failure, and renal dysfunction. It also serves as a tool for drug discovery, particularly in developing ANP analogs or NPR-A-targeted therapies. Clinically, ANP-based therapies, such as carperitide, have been approved in some regions for acute heart failure management, highlighting its translational potential. Additionally, recombinant NPPA is employed in diagnostic assays to measure ANP levels, aiding in the assessment of cardiac stress and disease progression.

Ongoing studies explore its role in metabolic disorders, inflammation, and fibrosis, broadening its therapeutic relevance. However, challenges like peptide stability and delivery efficiency drive innovations in formulation and targeted delivery systems. Overall, recombinant NPPA remains a pivotal molecule in both understanding cardiovascular biology and advancing precision medicine approaches.